Stella Xu - 18 Mar 2022 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Role
Director
Signature
/s/ Mustapha Parekh, Attorney-in-Fact
Issuer symbol
DSGN
Transactions as of
18 Mar 2022
Net transactions value
-$11,266,197
Form type
4
Filing time
22 Mar 2022, 19:26:18 UTC
Previous filing
20 Sep 2021
Next filing
16 Jun 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DSGN Common Stock Sale $10,514,364 -552,225 -12% $19.04 4,168,605 18 Mar 2022 See footnote F1, F2
transaction DSGN Common Stock Sale $268,488 -13,200 -0.32% $20.34 4,155,405 18 Mar 2022 See footnote F2, F3
transaction DSGN Common Stock Sale $456,240 -24,000 -0.58% $19.01 4,131,405 21 Mar 2022 See footnote F2, F4
transaction DSGN Common Stock Sale $27,105 -1,455 -0.04% $18.63 4,129,950 22 Mar 2022 See footnote F2, F5
holding DSGN Common Stock 10,000 18 Mar 2022 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.8726, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F2 The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.70, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.30, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.51 to $18.835, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.